Death-associated protein kinase 1 (DAPK1) is a calcium/calmodulin-regulated serine-threonine kinase encoded by DAPK1. It integrates stress signaling, apoptosis programs, and excitotoxic pathways relevant to neurodegeneration.[1][2] DAPK1 activity has been linked to synaptic dysfunction and neuronal loss in Alzheimer's Disease and ischemic/degenerative contexts through NMDA receptor and tau-related signaling intersections.[2:1][3]
DAPK1 is a large (~160 kDa) multidomain kinase with a modular architecture that enables context-dependent activation. The N-terminal catalytic domain contains the serine/threonine kinase active site, followed by a calmodulin (CaM) autoregulatory segment that inhibits kinase activity in the absence of calcium/CaM binding.[1:1] Downstream of the CaM domain are eight ankyrin repeats that mediate protein-protein interactions, a P-loop region, and a C-terminal cytoskeletal-binding death domain.[1:2][4] Autophosphorylation at Ser308 within the CaM regulatory segment serves as a key inhibitory modification — dephosphorylation of this site by protein phosphatase 2A or calcineurin activates the kinase.[4:1] The death domain anchors DAPK1 to the actin cytoskeleton and is essential for its pro-apoptotic function, distinguishing it from the shorter family members DAPK2 and DAPK3.[1:3]
Under physiological conditions, DAPK1 participates in multiple cellular processes. It regulates cytoskeletal dynamics through phosphorylation of myosin light chain, contributing to membrane blebbing and cell motility.[1:4] DAPK1 also promotes autophagy by phosphorylating beclin-1 at Thr119, disrupting its inhibitory interaction with Bcl-2 and thereby activating the class III PI3K complex required for autophagosome formation.[5] In the immune system, DAPK1 functions as a tumor suppressor by linking cytokine signaling to apoptosis — loss of DAPK1 expression through promoter methylation is common across multiple cancer types.[1:5][4:2] In neurons, balanced DAPK1 activity is important for survival-versus-pruning decisions during development, and its expression is tightly regulated to prevent aberrant cell death.[2:2]
DAPK1 directly binds the GluN2B (NR2B) subunit of NMDA receptors at residues 1292–1304, phosphorylating Ser1303 to enhance receptor channel conductance and calcium influx.[2:3] This interaction amplifies excitotoxic injury — genetic deletion of DAPK1 or disruption of the DAPK1-GluN2B interface protects against ischemic brain damage in mouse stroke models.[2:4] In the context of chronic neurodegeneration, sustained DAPK1-mediated potentiation of extrasynaptic NMDA receptors may contribute to the excitotoxic component of Alzheimer's Disease pathology.[6]
DAPK1 promotes tau hyperphosphorylation through both direct and indirect mechanisms. It activates downstream kinases including GSK-3β and CDK5, which phosphorylate tau at multiple AD-relevant epitopes.[3:1] Kim et al. (2014) demonstrated that DAPK1 directly phosphorylates the microtubule-binding repeat domain of tau, promoting its detachment from microtubules and facilitating neurofibrillary tangle formation.[3:2] DAPK1 expression is elevated in hippocampal neurons of AD patients compared to age-matched controls, correlating with Braak staging of tau pathology.[3:3][7]
DAPK1 modulates amyloid-beta production by phosphorylating the amyloid precursor protein (APP) at Thr668 and by regulating the activity of gamma-secretase components.[7:1] Overexpression of DAPK1 in neuronal cultures increases Aβ42 secretion, while DAPK1 knockdown reduces amyloidogenic processing.[7:2] This dual involvement in both tau and amyloid pathways positions DAPK1 at a mechanistic convergence point in AD pathogenesis.
While DAPK1-mediated beclin-1 phosphorylation normally promotes protective autophagy, chronically elevated DAPK1 activity in diseased neurons may contribute to excessive or dysregulated autophagic flux, potentially exacerbating lysosomal dysfunction observed in Alzheimer's and Parkinson's Disease.[5:1][8]
DAPK1 represents a mechanistically compelling but clinically early-stage therapeutic target for neurodegeneration:
Bialik S, Kimchi A. The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem. 2009. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Tu W, Xu X, Peng L, et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell. 2010. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kim BM, You MH, Chen CH, et al. Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. Cell Death Dis. 2014. ↩︎ ↩︎ ↩︎ ↩︎
Singh P, Bhatt LK. Death associated protein kinase 1 (DAPK1): a key player in tau hyperphosphorylation and neurodegeneration. Mol Neurobiol. 2020. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Zalckvar E, Berissi H, Mizrachy L, et al. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep. 2009. ↩︎ ↩︎
Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010. ↩︎ ↩︎
Kim BM, You MH, Chen CH, et al. DAPK1 is a mediator of the adverse effects of amyloid-beta peptide on tau phosphorylation and toxicity. J Biol Chem. 2016. ↩︎ ↩︎ ↩︎
Shi Y, Bhatt LK. DAPK1 in neurodegeneration: from molecular mechanisms to therapeutic strategies. J Neuroinflammation. 2022. ↩︎ ↩︎